Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05454189 · ClinicalTrials.gov registry record · NA
Safety of Extending The Routine Flushing Of Implanted Port Devices From 4 Weeks To 12
A NA study of Maintenance of Implanted Port Devices, sponsored by Essentia Health.
- Recruiting
- Registry status
- NA
- Development phase
- 400
- Enrollment target
- 17
- Study locations
NCT05454189: Recruiting NA study of Maintenance of Implanted Port Devices, sponsored by Essentia Health.
NCT05454189 is a NA study of Maintenance of Implanted Port Devices that is actively recruiting participants, run by Essentia Health. The registered enrollment target is 400 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (72% lower). The trial reports 17 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05454189, a NA study of Maintenance of Implanted Port Devices, is actively recruiting participants, sponsored by Essentia Health.
- RECRUITING
- Registry status
- NA
- Development phase
- 400 participants
- Enrollment target
- 17
- Study locations
Study Summary
Implanted port devices (IPD) play an essential role in the safe administration of cancer treatments by providing a device to safely administer caustic chemotherapy agents. The current recommended frequency of flushing the IPD per manufacturers guidelines is every 4-6 weeks. The purpose of this study is to find out if extending IPD flushes to every 12 weeks is safe and if it is just as effective as every 4 week flushing.
Primary Outcome
IPD patency without major complication
Conditions Studied
Interventions
- DEVICE Reduced IPD Flush Schedule
- DEVICE Standard IPD Flush Schedule
Study Locations (17)
Minnesota
- Mayo Clinic Health System - Albert Lea - Albert Lea
- Essentia Health St. Joseph's Medical Center - Brainerd
- Essentia Health Deer River Clinic - Deer River
- Essentia Health St Mary's Detroit Lakes Clinic - Detroit Lakes
- Essentia Health Duluth Clinic - Duluth
- Essentia Health Fosston - Fosston
- Fairview Grand Itasca Clinic & Hospital - Grand Rapids
- Essentia Health Hibbing Clinic - Hibbing
- Fairview Range Medical Center - Hibbing
- Mayo Clinic Health System - Mankato - Mankato
- Monticello Cancer center - Monticello
- Essentia Health Park Rapids - Park Rapids
- Fairview Northland Medical Center - Princeton
- Essentia Health Sandstone - Sandstone
- Essentia Health Virginia Clinic - Virginia
- Sanford Worthington Medical Center - Worthington
North Dakota
- Essentia Health Fargo - Fargo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2022-10-11 |
| Est. Completion | 2025-12-31 |
| Phase | NA |
What NCT05454189 shows while recruiting
NCT05454189 is an interventional study that assigns participants to a tested intervention. The registered 400 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (72% lower).
The record links to 1 condition, with Maintenance of Implanted Port Devices appearing as the primary indexed condition, and to 2 interventions - of which Reduced IPD Flush Schedule is the first listed.
NCT05454189 lists 17 locations in 2 states (Minnesota, North Dakota).
Frequently Asked Questions
What is clinical trial NCT05454189 about?
NCT05454189 is a clinical study titled "Safety of Extending The Routine Flushing Of Implanted Port Devices From 4 Weeks To 12". Implanted port devices (IPD) play an essential role in the safe administration of cancer treatments by providing a device to safely administer caustic chemotherapy agents. The current recommended frequency of flushing the IPD per manufacturers guidelines is every 4-6 weeks. The purpose of this study...
What is the current status of trial NCT05454189?
This trial is currently recruiting. It is a NA study. The enrollment target is 400 participants. The study started on 2022-10-11. Estimated completion is 2025-12-31.
What conditions does trial NCT05454189 study?
This clinical trial studies the following conditions: Maintenance of Implanted Port Devices.
What interventions are being tested in trial NCT05454189?
The interventions under investigation include: Reduced IPD Flush Schedule (DEVICE), Standard IPD Flush Schedule (DEVICE).
Who is sponsoring clinical trial NCT05454189?
This trial is sponsored by Essentia Health, which has 17 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05454189 being conducted?
This trial has 17 study locations across Minnesota, North Dakota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05454189's enrollment target sits among peer trials
400 246th of 2000 higher than 1,734 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01665326 · 400 participants
Determination of CRIM Status and Longitudinal Follow-up of Individuals With Pompe Disease
- NCT02108054 · 400 participants · NA
Behavioral and Functional Task Development, Implementation, and Testing
- NCT02216500 · 400 participants · NA
Ketogenic Therapy Effects on Electrical and Metabolic Abnormalities in Epilepsy
- NCT02250352 · 400 participants
Core Biopsies for Establishing a Breast Tumor Tissue Repository
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI